Benralizumab (Fasenra) IL-5 receptor alpha subunit blockade — the afucosylated monoclonal antibody binding to IL-5Rα on eosinophils and basophils, inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and near-complete eosinophil depletion — represents the fastest-expanding targeted biologic in the global eosinophil-driven disease landscape, with the Eosinophilia Therapeutic Market reflecting benralizumab as the premium rapid-onset and steroid-reduction driver.

The eosinophilic disease burden creating the biologic foundation — severe eosinophilic asthma affecting 5–10% of all asthma patients (approximately 13–26 million globally), hypereosinophilic syndrome with 0.5–2 cases per 100,000 annually, and eosinophilic granulomatosis with polyangiitis (EGPA) representing a rare but devastating vasculitis — generates the massive targeted therapy demand. The benralizumab drug market valued at USD 1.42–1.69 billion in 2024 and projected to reach USD 2.98–3.06 billion by 2030–2033 at an 8.7–10.06% CAGR demonstrates the commercial scale. The broader eosinophilic asthma treatment market starting at USD 70.27 billion in 2026 reflects the massive addressable opportunity across eosinophil-driven conditions.

Direct eosinophil killing vs. ligand neutralization — benralizumab's unique afucosylated Fc domain enhancing ADCC-mediated eosinophil apoptosis versus mepolizumab and reslizumab's IL-5 ligand neutralization — demonstrates the mechanistic differentiation. This direct cell-killing approach's ability to achieve >90% eosinophil depletion within 24 hours of first dose, provide rapid exacerbation reduction (51% decrease), enable greater oral corticosteroid reduction (75% vs. 50% with mepolizumab), and maintain efficacy with 8-week dosing intervals creates the clinical superiority. The SIROCCO and CALIMA Phase III trials demonstrating sustained exacerbation reduction and lung function improvement support the evidence base.

Subcutaneous administration and patient convenience — the fixed-dose 30 mg prefilled syringe and autoinjector enabling home administration every 4 weeks for 3 doses then every 8 weeks, versus reslizumab's IV infusion requirement — demonstrates the delivery innovation. This administration profile's ability to reduce clinic visit burden, improve adherence, enable patient self-management, and support healthcare system efficiency creates the operational differentiation from IV alternatives. The 8-week maintenance dosing offering the longest interval among anti-IL-5 biologics represents the convenience advantage.

Expanding indications beyond asthma — the FDA approval for EGPA in 2024, ongoing trials in chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), and bullous pemphigoid — demonstrates the pipeline diversification. These expansion opportunities' ability to leverage the established safety profile, manufacturing infrastructure, and payer relationships across multiple eosinophil-driven diseases creates the portfolio synergy. The potential for hypereosinophilic syndrome (HES) approval based on the ongoing Phase III MANDARA trial represents the next indication milestone.

Do you think benralizumab's direct eosinophil-killing mechanism will eventually make it the dominant anti-IL-5 biologic across all eosinophil-driven diseases, or will mepolizumab's earlier market entry, established payer contracts, and broader indication portfolio maintain competitive parity?

What anti-IL-5 biologics and eosinophil-targeting therapies are currently available? Anti-IL-5/IL-5R categories: (1) Benralizumab (Fasenra) — anti-IL-5Rα; ADCC; SC; q8wk; AstraZeneca; (2) Mepolizumab (Nucala) — anti-IL-5; ligand neutralization; SC/IV; q4wk; GSK; (3) Reslizumab (Cinqair) — anti-IL-5; IV; q4wk; Teva; (4) Dupilumab (Dupixent) — anti-IL-4Rα; IL-4/IL-13 blockade; SC; q2wk; Regeneron/Sanofi; (5) Tezepelumab (Tezspire) — anti-TSLP; broad; SC; q4wk; AstraZeneca/Amgen; indications: severe eosinophilic asthma; EGPA; CRSwNP; EoE (investigational); HES (investigational); eosinophilic esophagitis; pricing: benralizumab — USD 30,000–40,000/year; mepolizumab — USD 30,000–35,000/year; reslizumab — USD 25,000–35,000/year; dupilumab — USD 35,000–45,000/year.

What is the cost and clinical positioning of benralizumab in eosinophilic diseases? Benralizumab economics: annual cost: USD 30,000–40,000; vs. mepolizumab: similar; vs. OCS: USD 1,000–5,000; vs. hospitalization: USD 10,000–50,000/exacerbation; clinical outcomes: 51% exacerbation reduction; 75% OCS reduction; >90% eosinophil depletion; rapid onset; q8wk dosing; reimbursement: Medicare Part B; commercial; prior authorization; eosinophil count >150/µL required; market share: anti-IL-5 class — 25–30% of severe asthma biologics; benralizumab — 35–40% of anti-IL-5; growth: 8–10% CAGR; indication expansion driving volume.

#Eosinophilia #Benralizumab #Fasenra #AntiIL5 #SevereAsthma #EosinophilicAsthma #TargetedBiologic #SteroidSparing